H&E

AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology

Retrieved on: 
Monday, November 27, 2023
WSI, H&E, STIL, Patient, Tumor microenvironment, ITIL, TME, Therapy, Prognosis, Cancer, Analyser, Biomarker, Recurrence, AI, Neoplasm, TIL, Medical imaging, Medical device

SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, published a new study in npj Precision Oncology (Nature Partner Journal) , using Lunit SCOPE IO to predict prognosis in stage II–III colon cancer via AI-powered spatial analysis of tumor-infiltrating lymphocytes (TIL).

Key Points: 
  • SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, published a new study in npj Precision Oncology (Nature Partner Journal) , using Lunit SCOPE IO to predict prognosis in stage II–III colon cancer via AI-powered spatial analysis of tumor-infiltrating lymphocytes (TIL).
  • This study showed that Lunit SCOPE IO and the power of AI for spatial TIL analysis can provide clinicians with a practical and efficient tool to enhance prognosis prediction.
  • Traditionally recognized as a biomarker that can be related to cancer prognosis, TIL densities in the tumor microenvironment (TME) offer valuable insights into the patient's immune response to the tumor.
  • This result suggests that AI-powered TIL analysis can provide practical and reliable prognostic information for stage II–III colon cancer.

H&E Equipment Services Expands Presence in Central and Southern California, Acquires Rental Assets of Giffin Equipment

Retrieved on: 
Wednesday, November 1, 2023
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Urban Planning, REIT, H&E, City, Acquisition, Lease

H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the acquisition of the equipment rental assets of Giffin Equipment (“Giffin”), a California-based provider of non-residential construction and industrial equipment.

Key Points: 
  • H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the acquisition of the equipment rental assets of Giffin Equipment (“Giffin”), a California-based provider of non-residential construction and industrial equipment.
  • The acquisition, which closed earlier today, includes three branch locations and a fleet size, as measured by original equipment cost, of approximately $13.4 million.
  • Brad Barber, chief executive officer of H&E Equipment Services, Inc., detailed the importance of the acquisition, stating, “The addition of Giffin’s equipment rental assets and facilities increases our branch density and assists in bridging our existing locations in Central and Southern California.
  • Throughout Giffin’s 93-year history in California, its employees have maintained a focus on strong customer service, reliable equipment, and equipment solutions.

Ultivue announces launch of new configurable multiplex spatial panels at the Society for Immunotherapy of Cancer 2023 meeting

Retrieved on: 
Monday, October 30, 2023
Research, Biomarker, Society for Immunotherapy of Cancer, Product management, Cell, Drug development, SITC, Immunotherapy, Workflow, H&E, Society, Associate, Vaccine, Medical imaging

Pre-optimized ready-to-use kits with OmniVUE panels will be delivered within four weeks of request, with no additional development costs.

Key Points: 
  • Pre-optimized ready-to-use kits with OmniVUE panels will be delivered within four weeks of request, with no additional development costs.
  • Ultivue's biomarker library currently includes 24 validated immune biomarkers with additional biomarkers of clinical relevance being added continually.
  • OmniVUE panels leverage Ultivue's proprietary InSituPlex ® platform technology to enable a fast and simple assay workflow with high-quality, reliable, and quantitatively verified assay performance.
  • To learn more about OmniVUE, you can reach out to the Ultivue team through the media contacts below or register to attend the OmniVUE product launch event at SITC 2023.

Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy

Retrieved on: 
Friday, October 27, 2023
MSD, Principal, Data analysis, Biomarker, Therapy, Marie Cassidy, Pembrolizumab, Monroe Dunaway Anderson, TIL, SCOPE, Immunotherapy, H&E, Tumor microenvironment, University, Cancer, AI, MD Anderson Cancer Center, Patient, Medical imaging, Merck

SEOUL, South Korea, Oct. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a research collaboration with The University of Texas MD Anderson Cancer Center to analyze the use of Merck's (known as MSD outside the US and Canada) Keytruda (pembrolizumab), a type of immunotherapy drug used in cancer treatment, in multiple cancer types. The project will use Lunit's proprietary AI solution for tissue data analysis, Lunit SCOPE IO.

Key Points: 
  • The project will use Lunit's proprietary AI solution for tissue data analysis, Lunit SCOPE IO.
  • Lunit will collaborate with Aung Naing, M.D., professor of Investigational Cancer Therapeutics at MD Anderson, as the lead Principal Investigator (PI) for this study.
  • "There is currently a lack of effective biomarkers for immunotherapy," said Brandon Suh, CEO of Lunit.
  • The landscape is changing rapidly and state-of-art technologies such as AI are playing a significant role in enabling new biomarkers.

H&E Equipment Services, Inc. Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, October 26, 2023
Other Construction & Property, Architecture, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Renting, Security (finance), Continuous operation, Eastern Time Zone, Tax, Adobe Acrobat, EBITDA, GAAP, Acquisition, Net income, Growth, H&E, Depreciation, Administration, Bookkeeping, Video game, Adjustment

Average rental rates, excluding One Source, increased 4.9% compared to the third quarter of 2022, and 1.2% compared to the second quarter of 2023.

Key Points: 
  • Average rental rates, excluding One Source, increased 4.9% compared to the third quarter of 2022, and 1.2% compared to the second quarter of 2023.
  • Dollar utilization of 41.5% compared to 42.7% in the third quarter of 2022 and 40.6% in the second quarter of 2023.
  • Time utilization (based on original equipment cost) was 70.0% in the third quarter of 2023 compared to 73.3% in the third quarter of 2022.
  • Gross margins on used equipment sales improved to 58.5% in the third quarter of 2023 compared to 53.7% in the third quarter of 2022.

U.S. FDA Grants Paige Breakthrough Device Designation for Cancer Detection in Breast Lymph Nodes

Retrieved on: 
Thursday, October 26, 2023
Technology, Biotechnology, FDA, Health, Pharmaceutical, Artificial Intelligence, Oncology, Other Technology, Research, Medical Devices, Software, Health Technology, Science, Clinical Trials, Regulation of tobacco by the U.S. Food and Drug Administration, Marie Cassidy, Lymph, Pathology, Doctor of Philosophy, Ziehl–Neelsen stain, Multimedia, Breast cancer, H&E, Cancer, Patient, Diagnosis, Medical imaging, Pharmaceutical industry

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced today that the U.S Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Paige Lymph Node1, an AI application used to detect breast cancer metastases in lymph node tissue.

Key Points: 
  • Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced today that the U.S Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Paige Lymph Node1, an AI application used to detect breast cancer metastases in lymph node tissue.
  • Paige Lymph Node is the first AI application of its kind to receive Breakthrough Device Designation from the FDA.
  • Paige Lymph Node detects the presence of breast cancer metastases with near-perfect sensitivity3.
  • 1In the United States, Paige Lymph Node is for research use only and should not be used in diagnostic procedures.

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Retrieved on: 
Monday, October 23, 2023
ESMO, Health, SCCHN, Head, Poster, Paclitaxel, Partnership, H&E, Digital pathology, ANL, CMO, NORTH, Patient, Medical imaging, Buparlisib

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.

Key Points: 
  • SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.
  • We are extremely pleased the study was recognized for its quality and success,” said Dr. Lars Birgerson, President & CMO of Adlai Nortye.
  • The poster, #869P, was presented at the Head and Neck Cancers poster session on Sunday, October 22, 2023.
  • The Best Poster Award was given at the conclusion of the Sunday Poster Session.

H&E Equipment Services Announces 2023 Third Quarter Earnings and Conference Call Date

Retrieved on: 
Thursday, October 19, 2023
Adobe Acrobat, Rouge, H&E, Eastern Time Zone, Eastern, Rare-earth element, Television, Cryptocurrency

Baton Rouge, La., Oct. 19, 2023 (GLOBE NEWSWIRE) -- H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that it will release its 2023 third quarter financial results before the market on Thursday, October 26, 2023.

Key Points: 
  • Baton Rouge, La., Oct. 19, 2023 (GLOBE NEWSWIRE) -- H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that it will release its 2023 third quarter financial results before the market on Thursday, October 26, 2023.
  • The Company will also hold a conference call to discuss third quarter results on Thursday, October 26, 2023, at 10:00 a.m. (Eastern Time).
  • A telephonic replay will become available after 1:00 p.m. (Eastern Time) on October 26, 2023, and will continue through November 2, 2023, by dialing 877-344-7529 and entering the confirmation code 9392769.
  • The live broadcast of H&E Equipment Services’ quarterly conference call will be available online at www.he-equipment.com on October 26, 2023, beginning at 10:00 a.m. (Eastern Time) and will continue to be available for 30 days.

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

Retrieved on: 
Tuesday, October 24, 2023
TKI, Bevacizumab, Patient, Pemetrexed, Arm, PC, NSCLC, Carboplatin, CDX, ESMO, Progression-free survival, III, Therapy, Lung cancer, Cisplatin, PFS, European Society for Medical Oncology, Phenotype, Research, TIL, JCO, Journal, Samsung Medical Center, ALK, Journal of Clinical Oncology, Annual general meeting, Immunotherapy, H&E, ORR, Oncology, ABCP, Mutation, EGFR, Pharmaceutical industry, Medical imaging

Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.

Key Points: 
  • Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.
  • Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research.
  • Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment.
  • "We aim for Lunit SCOPE IO to continue to make immune phenotyping a quantitative biomarker readily accessible for research, clinical use, and companion diagnostics (CDx) business."

New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Congress, H&E, Mayo Clinic, Tumor microenvironment, Abstract, Research, NSCLC, AI, HNSCC, Therapy, Data, Lung cancer, Cancer, TIL, Marie Cassidy, European Society for Medical Oncology, ESMO, Oncology, Cholangiocarcinoma, PPV, Genotype, Head, Neoplasm, ICI, Phenotype, Affirmative action, Progression-free survival, HER2, MET, Patient, WSI, BTC, Medical device, Medical imaging

SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 9 studies at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, to be held in Madrid, Spain, from October 20-24.

Key Points: 
  • A collaborative study indicated that AI-based immune phenotyping can predict therapy outcomes in advanced biliary tract cancer (BTC) patients who are planning to be treated with anti-PD-1 therapy.
  • In the study, the research team defined the immune phenotype of the WSI samples via Lunit SCOPE IO, Lunit's AI TIL (tumor-infiltrating lymphocytes) analyzer.
  • In another study, HER2 (human epidermal growth factor receptor-2) scoring in biliary tract cancer was evaluated using Lunit SCOPE HER2.
  • Another study aimed to predict multiple druggable mutations in non-small cell lung cancer (NSCLC) based on AI analysis of H&E images.